Perspective Therapeutics(US:CATX) GlobeNewswire News Room·2024-10-16 11:00Core Insights - Perspective Therapeutics, Inc. has commenced the first shipment and patient dosing from its second manufacturing facility for 203Pb- and 212Pb-labeled radiopharmaceuticals, marking a significant milestone for the company [1][3] Manufacturing Facility - The new facility located in Somerset, New Jersey, is operational and will supply investigational products for VMT-α-NET clinical studies, complementing the existing facility in Coralville, Iowa [2] - The Somerset facility has three manufacturing suites that comply with Current Good Manufacturing Practice (cGMP) requirements and is expected to meet future clinical trial and commercial demands in the Northeastern U.S. [2] - Prior to its acquisition by Perspective in March 2024, the Somerset facility was operated by Lantheus Holdings, Inc., which produced the FDA-approved radiopharmaceutical Azedra [2] Company Strategy and Commitment - The operational status of the Somerset facility, achieved seven months post-acquisition, allows the company to accelerate the delivery of investigational products and new therapies pending approval [3] - The company aims to enhance its manufacturing and supply chain capabilities, reflecting its commitment to providing targeted alpha-particle therapies to patients in need [3] - Perspective plans to strategically replicate its efforts by adding more sites to support key treatment hubs across the U.S. [3] Product Development - Perspective Therapeutics is focused on developing advanced treatment applications for cancers using proprietary technology that utilizes the alpha-emitting isotope 212Pb [4] - The company is advancing its melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs, which are currently in Phase 1/2a imaging and therapy trials at leading academic institutions [5] - A proprietary 212Pb generator has been developed to secure key isotopes for clinical trial and commercial operations [5]